Physician profile
Amber Anderson
NPI 1184359309
$8,982.01
in general payments reported to CMS, 2019-2025
45 companies · $4,401 in 2025
The $4,401 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $526 · 2024: $3,933 · 2025: $4,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,333 · Travel and Lodging: $431 · Education: $96.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,332.54 |
| Travel and Lodging | $430.97 |
| Education | $96.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,044.24 | 2023-2025 | |
| Ucb, INC. | $1,004.55 | 2024-2025 | Fintepla, Briviact, Nayzilam |
| Emd Serono, INC. | $567.00 | 2024-2025 | Mavenclad |
| Pfizer INC. | $545.83 | 2024-2025 | |
| Argenx US, INC. | $523.36 | 2024-2025 | Vyvgart Hytrulo |
| Neurelis, INC. | $473.72 | 2023-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $461.94 | 2023-2025 | Ingrezza |
| Livanova USA, INC. | $430.97 | 2025 | Vns Therapy |
| Teva Pharmaceuticals USA, INC. | $402.97 | 2024-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $373.51 | 2024-2025 | Ultomiris |
| Lundbeck LLC | $332.43 | 2023-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $308.53 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $255.45 | 2024-2025 | Nuplazid |
| Eisai INC. | $254.57 | 2023-2025 | |
| Sk Life Science, INC. | $211.51 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $211.42 | 2025 | Tysabri, Vumerity |
| Lilly USA, LLC | $158.14 | 2023-2025 | Amyvid, Kisunla, Emgality |
| E.R. Squibb & Sons, L.L.C. | $140.65 | 2022-2023 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $130.13 | 2024-2025 | |
| Celgene Corporation | $110.01 | 2024-2025 | Zeposia |
| Kyowa Kirin, INC. | $104.55 | 2023-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $95.03 | 2023-2025 | Nuedexta |
| Amneal Pharmaceuticals LLC | $88.82 | 2025 | Crexont |
| Scilex Pharmaceuticals INC. | $82.17 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $79.65 | 2024-2025 | Acthar |
| Genzyme Corporation | $63.92 | 2025 | |
| Csl Behring | $63.00 | 2024 | Hizentra |
| Astrazeneca Pharmaceuticals LP | $54.99 | 2023-2025 | Wainua |
| Janssen Biotech, INC. | $48.20 | 2025 | |
| Sumitomo Pharma America, INC. | $46.88 | 2023-2024 | Aptiom |
| Genentech USA, INC. | $37.87 | 2024 | Ocrevus, Ocrevus Zunovo |
| Cycle Pharmaceuticals INC | $27.32 | 2024 | Tascenso Odt |
| Medtronic, INC. | $25.43 | 2024 | Intellis Adaptivestim |
| Jazz Pharmaceuticals INC. | $23.78 | 2025 | |
| Octapharma USA, INC. | $23.46 | 2025 | Panzyga |
| Averitas Pharma INC. | $23.08 | 2024 | Qutenza |
| Mdd US Operations, LLC | $21.42 | 2024 | Gocovri |
| Axsome Therapeutics, INC. | $19.86 | 2025 | Symbravo |
| Coopersurgical, INC. | $19.00 | 2024 | Paragard T 380a |
| Amgen INC. | $17.19 | 2025 | Uplizna |
| Impel Pharmaceuticals LLC | $16.64 | 2025 | Trudhesa |
| Banner Life Sciences, LLC | $15.17 | 2024 | |
| Boston Scientific Corporation | $14.94 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Vanda Pharmaceuticals INC. | $14.73 | 2025 | Ponvory |
| Tg Therapeutics, INC. | $13.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.